1. Home
  2. AUPH vs IMAX Comparison

AUPH vs IMAX Comparison

Compare AUPH & IMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$14.25

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Imax Corporation

IMAX

Imax Corporation

HOLD

Current Price

$37.21

Market Cap

2.1B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUPH
IMAX
Founded
1993
1967
Country
Canada
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.1B
IPO Year
2014
1997

Fundamental Metrics

Financial Performance
Metric
AUPH
IMAX
Price
$14.25
$37.21
Analyst Decision
Buy
Strong Buy
Analyst Count
4
9
Target Price
$17.25
$44.44
AVG Volume (30 Days)
1.1M
1.0M
Earning Date
05-11-2026
04-22-2026
Dividend Yield
N/A
N/A
EPS Growth
5075.00
31.25
EPS
2.07
0.63
Revenue
$283,055,000.00
$410,212,000.00
Revenue This Year
$16.53
$9.80
Revenue Next Year
$16.24
$7.11
P/E Ratio
$7.06
$59.92
Revenue Growth
20.38
16.47
52 Week Low
$6.83
$20.48
52 Week High
$16.54
$43.16

Technical Indicators

Market Signals
Indicator
AUPH
IMAX
Relative Strength Index (RSI) 49.28 44.75
Support Level $13.52 $35.91
Resistance Level $15.23 $37.52
Average True Range (ATR) 0.45 1.12
MACD 0.03 -0.26
Stochastic Oscillator 36.73 32.17

Price Performance

Historical Comparison
AUPH
IMAX

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About IMAX Imax Corporation

Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.

Share on Social Networks: